
Last updated: 2026-10-13 16:18:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Werewolf Therapeutics, Inc. (HOWL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,98, with a market capitalisation of $47,61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,27 to $1,83. This page covers its latest market performance, valuation, price trends and company information.
$47,61M | |
$1,00 | |
$23,99 | |
$0,27 | |
$0,98 | |
120,35K | |
6,88M | |
-- | |
$1,83 | |
$0,27 | |
-- | |
-- |
Werewolf Therapeutics, Inc. (HOWL) is currently trading at $0,98 as of 2026-10-13 16:16:00, up 0,22% ($0,00) from the previous close of $0,98
During today's regular trading session, HOWL has traded between $0,27 and $23,99, with a trading volume of 120,35K shares. The current price is near the lower end of today's range.
Over the past seven days, Werewolf Therapeutics, Inc. (HOWL) moved from $0,93 to $0,98, representing a gain of 6,02% ($0,06).
The stock traded between $0,89 and $1,02 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 502,65 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45,8%
HOWL is currently trading at $0,98, placing it 45,8% of the way from its 52-week low of $0,27 to its 52-week high of $1,83. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Werewolf Therapeutics, Inc. (HOWL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.